May 24, 2024

Hey there! I’ve got some exciting news to share with you today. Biotech companies are turning to gene silencing as the next big thing in obesity drug research. This new approach uses RNA interference to silence genetic instructions for making problematic proteins, and could lead to longer-lasting therapies for obesity. Plus, a second case of bird flu has been reported in a farm worker, and UnitedHealth is facing lawsuits over its algorithm determining rehab coverage. But don’t worry, there’s also some good news on the COVID-19 front – Gilead’s antiviral drug has shown promise in defusing coronaviruses in mice.

In other news, pharmaceutical companies are experiencing a boost in their reputations thanks to the success of new anti-obesity drugs. Novo Nordisk’s Ozempic and Wegovy have become cultural and economic phenomena, and the public is largely giving drugmakers a pass on the high prices of these transformational treatments. Additionally, there’s been a safety risk cited for a weekly insulin from Novo Nordisk, and a second case of bird flu has been detected in a human worker at a Michigan dairy farm.

But it’s not all bad news – daily marijuana use has surpassed daily alcohol consumption in the US for the first time, and researchers have found that the appendix may play an important role in fighting off gastrointestinal infections. And if you’re looking to protect against cognitive decline, researchers have identified some factors that may help, such as exercise and a Mediterranean-style diet.

So, there you have it – some exciting developments in the world of healthcare and pharmaceuticals. Stay tuned for more updates and positive news in the future!

Take care,

Summy

Stay Well!